

Journal of Visualized Experiments

Absorbent microbiopsy sampling and RNA extraction for minimally invasive, simultaneous blood and skin analysis

--Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58614R2
Full Title:	Absorbent microbiopsy sampling and RNA extraction for minimally invasive, simultaneous blood and skin analysis
Keywords:	Microbiopsy; microsampling; skin; skin biopsy; blood sampling; Minimally invasive; microneedle; dermatology
Corresponding Author:	Tarl Prow, Ph.D. University of South Australia Mawson Lakes, SA AUSTRALIA
Corresponding Author's Institution:	University of South Australia
Corresponding Author E-Mail:	tarl.prow@unisa.edu.au
Order of Authors:	Benson U Wang Lei Miko Yamada Van LT Hoang Lynlee Li Lin Ross Flewell-Smith Nhung Dang Shoko Tomihara Tarl W Prow, Ph.D.
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	University of South Australia, Mawson Lakes Campus, Level 3, Building MM Mawson Lakes Blvd, Mawson Lakes SA 5095, Australia

16th August 2018

To Journal of Visualized Experiments

**Re: Revisions Required for Your JoVE Submission JoVE58614R1 -
[EMID:c7a70b95a307f5d5]**

Future Industries
Institute

Building X,
Mawson Lakes,
Adelaide SA 5095

GPO Box 2471
Adelaide
South Australia 5001
Australia

+61 8 8302 3404

FIIAdmin@unisa.edu.au

unisa.edu.au/fii

CRICOS Provider Number 00121B

Dear Editor,

I am writing to re-submit our original work entitled “Absorbent microbiopsy sampling and RNA extraction for minimally invasive, simultaneous blood and skin analysis” for publication.

We originally submitted this manuscript in June 2018 and resubmitted a revised version on 8th August 2018. It was suggested that the Protocol section needs further clarifications. We have made several major changes in the section as suggested: 1) Step-wise descriptions for steps 5.7 and 5.8 have been provided; 2) references to published materials about steps 5.7 and 5.8 have been added; 3) the essential steps have been highlighted in yellow in less than 2.75 pages. In addition, we have edited the document as suggested, proofread, removed headers from the Representative Results section and have revised the Table of Materials to include all the required reagents/equipment. Please let us know if there are any further changes needed.

The author guidelines for this publication have been fully met.

I would like to confirm that the authors of this manuscript have not published or submitted any related papers from the same study.

Sincerely,



Prof. Tarl Prow

TITLE:

Absorbent Microbiopsy Sampling and RNA Extraction for Minimally Invasive, Simultaneous Blood and Skin Analysis

AUTHORS & AFFILIATIONS:

Benson UW Lei^{1,2}, Miko Yamada¹, Van LT Hoang³, Lynlee L Lin², Ross Flewell-Smith¹, Nhung Dang^{1,2}, Shoko Tomihara², Tarl W Prow^{1,2}

¹Future Industries Institute, University of South Australia, Adelaide, Australia

²Faculty of Medicine, The University of Queensland, St. Lucia, Australia

³Faculty of Health, Queensland University of Technology, Brisbane, Australia

Email Addresses:

Benson UW Lei (u.lei@uq.edu.au)

Miko Yamada (miko.yamada@unisa.edu.au)

Van LT Hoang (v3.hoang@qut.edu.au)

Lynlee L Lin (l.li4@uq.edu.au)

Ross Flewell-Smith (ross.flewell-smith@unisa.edu.au)

Nhung Dang (nhung.dang@unisa.edu.au)

Shoko Tomihara (s.tomihara@uq.edu.au)

Corresponding Author:

Prof. Tarl W Prow

tarl.prow@unisa.edu.au

KEYWORDS:

Microbiopsy, microsampling, skin, skin biopsy, blood sampling, minimally invasive, microneedle, dermatology

SUMMARY:

In this article, we demonstrate how the absorbent microbiopsy technique is performed and how the sample can be used for RNA extraction for simple and simultaneous sampling of skin and blood in a minimally invasive manner.

ABSTRACT:

Conventional skin biopsy limits the clinical research that involves cosmetically sensitive areas or pediatric applications due to its invasiveness. Here, we describe the protocol for performing an absorbent microneedle-based device, absorbent microbiopsy, for minimally invasive sampling of skin and blood mixture. Our goal is to help facilitate rapid progress in clinical research, the establishment of biomarkers for skin disease and reducing the risk for clinical research participants. In contrast to conventional skin biopsy techniques, the absorbent microbiopsy can be performed within seconds and does not require intensive training due to its simple design. In this report, we describe the use of absorbent microbiopsy, including loading and application, on a male volunteer. Then, we show how to isolate RNA from the absorbed sample. Finally, we demonstrate the use of quantitative reverse transcription PCR (RT-qPCR) to quantify mRNA

expression levels of both blood (*CD3E* and *CD19*) and skin (*KRT14* and *TYR*). The methods that we describe utilize off the shelf kits and reagents. This protocol offers a minimally invasive approach for simultaneous sampling of skin and blood within the same absorbent microbiopsy matrix. We have found human ethics committees, clinicians and volunteers to be supportive of this approach to dermatological research.

INTRODUCTION:

Skin biopsy is one of the most essential techniques in dermatology for skin sampling and subsequent diagnosis of skin diseases through histopathological assessment. The biopsy technique involves a medical professional using a blade or punch biopsy to remove the suspicious lesion on patient's skin for examination¹. Though the technique is effective, it is highly invasive and limits clinical research as the end point usually involves molecular biology techniques^{2,3}. Molecular analysis of skin diseases has the potential to provide highly specific biological information that histopathological analysis cannot facilitate drug discovery and disease diagnosis^{4,5}. Besides, the sample demand in most molecular techniques is comparatively small and may lead to a reduction in animal use and permit a larger number of replicates. Therefore, there is a clear need for an alternative technique that enables molecular analysis in clinical research and lowers risk for participants.

To address such a need in the field, our group has developed a novel microneedle-based diagnostic platform, absorbent microbiopsy, that enables the collection of a tiny amount of skin mixed with blood in a simple and minimally invasive manner⁶. The purpose of this publication is to describe the absorbent microbiopsy as a sampling tool to facilitate molecular analysis through RNA extraction in clinical research.

Previously, we have described the first version of microbiopsy, skin microbiopsy, which consists of a microneedle made of a three-layer steel plate design to extract tiny pieces of skin tissues⁷. The novelty of this device comes from the multiple contact points from the microneedle that permits efficient tissue extraction³. In contrast, a circular skin punch biopsy provides only one contact point and simply tears the skin without capturing any sample in some cases. Based on the skin microbiopsy, we recently developed the absorbent microbiopsy which has both blood and skin sampling capabilities. The device has been shown to be feasible for use in resource-poor areas in a recent epidemiological study⁶.

Due to its simple design, the absorbent microbiopsy can be performed within a few seconds and does not require extensive training. Additionally, local anesthetic is not needed, and the application site does not cause scarring. The present protocol enables researchers or medical professionals without relevant sampling training to obtain targeted skin data for molecular analysis. We expect microsampling devices to become routine in skin research in the future.

Although the microbiopsy has been reported in other skin disease studies that involved molecular diagnostic techniques^{6,8-10}, such as human papilloma virus DNA detection, this protocol is the first to demonstrate the details of the sample extraction and processing techniques for the absorbent microbiopsy. Further, this is the first report describing the relative gene expression

profiling of skin and blood cells in microbiopsy samples.

PROTOCOL:

The study was approved by Metro South Human Research Ethics Committee and the University of Queensland Human Research Ethics Committee (HREC-13-QPAH-551 and UQ2013001551).

1. Absorbent Microbiopsy Fabrication

1.1. Laser cut microneedle parts from 50 μm medical-grade stainless steel sheet and absorbent layer (filter paper), respectively (**Figure 1**).

Note: Other parts, including the plunger and the case, of the device are fabricated with rapid-prototyping techniques, such as 3D printing.

1.2. Soak all the parts, except for the absorbent layer, in 70% ethanol (EtOH) for 5 min and airdry them for 30 min afterwards.

1.3. Assemble the three-layer microneedle, with the absorbent layer in the middle (**Figure 1a**).

1.4. Insert the assembled microneedle into the slit of plunger.

1.5. Put on the spring and insert the plunger into the case (**Figure 1c**). Avoid the microneedle touching anything in the assembling procedure to ensure the needle quality.

1.6. Seal the assembled absorbent microbiopsy in a package for γ -radiation sterilization before using.

2. Sampling with the Absorbent Microbiopsy

2.1. Wear disposable gloves, and spray hands and tools, such as forceps, with 70% EtOH.

2.2. Sanitize the application site with an alcohol wipe.

2.3. Remove the microbiopsy from the γ -radiation sterilized package without touching the microneedle in the process.

2.4. Load the device by pulling the plunger to compress the spring until there is a 'click' sound and the plunger locks in place.

2.5. Aim the device at the skin to be sampled, ensuring that the sampling area is in a fixed position.

2.6. Ensure that the device is approximately perpendicular to the skin, then apply ≥ 1 kg of force to the device onto the skin.

Note: Applying force downwards into the skin is required to ensure sufficient penetration of the microneedle.

2.7. Press the trigger and hold the device in place for a minimum of 10 s for the blood sample to be absorbed.

Note: If the device is released before 10 s, there is a higher chance of variation in any analyses.

3. RNA Extraction

Note: The RNA extraction procedures were modified from manufacturers' protocol for optimal isolation of RNA from microbiopsied sample. All the reagents and column used in RNA extraction are included in the kit unless indicated otherwise.

3.1. Pull out the plunger and absorbent microneedle from the case by hands gently. Ensure that the tip of the microneedle does not come into contact with anything during removal.

3.2. Remove the absorbent microneedle from the plunger. Hold onto the two holes on the microneedle with a pair of sterile forceps and pull it out.

3.3. Put the intact microneedle in a 2 mL microcentrifuge tube (not from the RNA isolation kit; see **Table of Materials**) prefilled with 50 μ L of Extraction Buffer, with the needle side facing down towards the bottom. To minimize sample loss, leave the tube on dry ice for 5 min before processing the sample.

3.4. Vortex briefly (3 – 5 s) to remove some of the sampled materials from the tip.

3.5. Incubate the microneedle in the tube on a rocker for 30 min at 42 °C.

Note: The buffer solution will be absorbed into the absorbent layer immediately.

3.6. Place the top part of the microneedle (the opposite side from the needle) level with the top edge of the 2 mL microfuge tube using sterile forceps.

3.7. Close the lid of the tube such that the top of the microneedle is held in place between the cap and tube.

3.8. Spin the tube at 16,000 x g or at maximum speed for 30 s to remove the sampled materials from the absorbent layer of the device.

3.9. Remove the microneedle carefully with forceps without dipping back into the buffer solution. Keep the tube and discard the microneedle.

177 3.10. Centrifuge the samples at 3,000 x g for 2 min. Pipette the supernatant containing the
178 extracted RNA carefully into a new microcentrifuge tube.

180 3.11. Add 250 µL of Conditioning Buffer onto the purification column filter membrane and
181 incubate for 5 min at room temperature.

183 3.12. Centrifuge the column in the collection tube at 16,000 x g or at maximum speed for 1 min.

185 3.13. Add 50 µL of 70% EtOH into the collected sample from Step 3.9. Mix well by gently
186 pipetting up and down.

188 3.14. Transfer the mixture (~100 µL) into the preconditioned purification column.

190 3.15. Centrifuge for 2 min at 100 x g immediately, followed by a centrifugation at 16,000 x g for
191 30 s to remove the flow-through.

193 3.16. Add 100 µL of Wash Buffer 1 (W1) into the purification column and centrifuge for 1 min
194 at 8,000 x g.

196 3.17. Prepare DNase solution by adding 5 µL of DNase I Stock Solution to 35 µL of Buffer RDD
197 in a separate microcentrifuge tube for each sample. Mix by gently inverting.

199 Note: The DNase treatment is to be performed on the purification column, instead of in the PCR
200 plate afterwards, because of the quantity of the sample.

202 3.18. Add 40 µL of DNase incubation mix directly into the purification column membrane.
203 Incubate at room temperature for 15 min.

205 3.19. Add 40 µL of W1 into the purification column membrane. Centrifuge at 8,000 x g for 15 s.

207 3.20. Pipette 100 µL of Wash Buffer 2 (W2) into the purification column after the DNase
208 treatment and centrifuge for 1 min at 8,000 x g.

210 3.21. Add another 100 µL of W2 into the purification column and centrifuge for 2 min at 16,000
211 x g. Check the purification column for any residual wash buffer. Re-centrifuge at 16,000 x g for 1
212 min if any wash buffer remains.

214 3.22. Transfer the purification column to a new 0.5 mL microcentrifuge tube provided in the
215 kit.

217 3.23. Pipette 11 µL of RNase-free water (not provided in the RNA isolation kit), instead of
218 Elution Buffer (EB), directly onto the membrane of the purification column. Gently touch the tip
219 of the pipette to the surface of the membrane while dispensing the RNase-free water to ensure
220 maximum absorption of RNase-free water into the membrane. Incubate at room temperature

for 2 min.

3.24. Centrifuge the column for 1 min at 1,000 x g to distribute the RNase-free water in the column, then centrifuge for 16,000 x g at 1 min to elute RNA.

Note: RNA quantification is not recommended due to the small quantity of the sample.

3.25. Stop point #1: Store the total RNA sample at -80 °C if cDNA synthesis is not performed immediately.

Note: Avoid freezing if not necessary given the low concentration of RNA sample.

4. cDNA Synthesis

4.1. Thaw the frozen sample on ice (from Step 3.25).

4.2. Synthesize cDNA from total RNA with cDNA synthesis kit according to the procedure below.

4.3. Prepare the reaction mix: 11 µL of total RNA, 4 µL of 5x TransAmp Buffer, 1 µL of reverse transcriptase, 4 µL of DNase/RNase-free water. Mix gently by pipetting.

4.4. Run reverse transcription on a thermal cycler apparatus: 25 °C for 10 min, 42 °C for 15 min, followed by a final reverse transcriptase inactivation step at 85 °C for 5 min.

4.5. Stop point #2: Store the reverse transcribed sample at -80 °C until use.

5. qPCR Reaction and Data Analysis

Note: The primers for qPCR reactions were designed to span intron boundaries to avoid the amplification of genomic DNA using NCBI Primer BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast/). The reference gene used in this study is *RPLP0* (see the Discussion section for more information).

5.1. Thaw the frozen sample on ice (from Step 4.5).

5.2. Perform qPCR with the qPCR master mix kit according to the procedure below.

5.3. Prepare master mix containing the followings per reaction: 5 µL of 2x qPCR reaction mix, 0.4 µL of 10 µM forward primer, 0.4 µL of 10 µM reverse primer, 2.2 µL of DNase-free water. Mix gently by pipetting. Set up the samples in triplicates.

5.4. Pipette 8 µL of the master mix into each well of a 384-well PCR plate first and then 2 µL of cDNA from each sample (a total of 10 µL per well).

Note: No template control (NTC) and no reverse transcriptase control (-RT) are included as negative controls.

5.5. Seal the plate with adhesive film, and centrifuge briefly.

5.6. Run the amplification reaction on a real-time thermal cycler: 95 °C for 2 min (polymerase activation), followed by 40 cycles of 95 °C for 5 s (denaturation), 60 °C for 10 s (annealing) and 72 °C for 10 s (extension).

5.7. Calculate the RNA concentration of samples by interpolating from a standard curve prepared from templates with known concentrations.

5.7.1. Create a **New Experiment** in the software.

5.7.2. Click **Define and Set Up Standards** to set up serial dilution for plates.

5.7.3. Select and arrange the wells for standards and samples. Click **Apply**.

5.7.4. Click **Analyze** in the Result tab to assess the standard curve. Confirm the slope, R^2 value, amplification efficiency and error meet the experimental criteria.

5.7.5. Check the quantities of the unknown samples visually on the standard curve based on their Ct values.

Note: The construction of standard curve, including the choice of dilution factor, is performed according to published protocols¹¹⁻¹³.

5.8. Perform gene expression analysis of mRNA by using the ΔC_t method (Ct is normalized to a reference gene).

5.8.1. Subtract the Ct value of target gene from the Ct value of reference gene to obtain the ΔC_t value.

5.8.2. Average the ΔC_t values of technical replicates.

5.8.3. Plot and analyze the gene expression with statistics software^{11,14} (see **Table of Materials**).

Note: Alternatively, the gene expression analysis is performed according to published protocols¹³.

REPRESENTATIVE RESULTS:

We have previously reported that the microneedle of the skin microbiopsy penetrates the skin approximately 500 μm deep⁷. The microneedle design of skin microbiopsy is highly similar to the

one on absorbent microbiopsy (**Figure 2a**). While the absorbent microbiopsy consisted of an absorbent layer in the middle for blood absorption, the skin microbiopsy contained a channel for mechanical capturing of skin tissues. The use of absorbent layer also led to a slight difference in the microneedle dimension (absorbent: 1.50 x 0.50 x 0.21 mm vs skin: 1.50 x 0.50 x 0.15 mm).

Figure 2b shows the application sites 5 min after absorbent and skin microbiopsies were applied on the left volar arm of male volunteer. Due to the similarity between the two microneedle designs, the application sites from both devices were comparable, with minor erythema. Both application sites were not noticeable after 48 h with no scars left behind. This supports the hypothesis that this minimally invasive device has the potential to help screen multiple application sites or to be performed on a regular basis.

Figure 2c shows a representative picture of the absorbent layer of the absorbent microbiopsy after being applied to the volar arm of a male volunteer. As shown in the figure, a few tiny pieces of skin were captured near the tip of the microneedle, and some blood was absorbed into the filter paper. This indicates that the device penetrated the skin and captured both skin and blood simultaneously within the same absorbent microbiopsy matrix. **Figure 2d** shows a post-sampling skin microbiopsy, the previous generation of microbiopsy, for comparison. The channel of the skin microbiopsy captured a small piece of skin, but the amount of blood on the microneedle was small relative to the absorbent microbiopsy. Both application sites were not noticeable within 48 h. In the experiment, the absorbent microbiopsy was applied with a 10-s holding time post-application, while the skin microbiopsy was immediately released after applying due to the difference in design.

As shown in **Figure 3a**, two groups of absorbent microbiopsy were involved in this experiment based on the application protocol: 'Immediate release' and '10-s holding'. For the 'Immediate release' group, the device was applied using the same original skin microbiopsy protocol, with the device being removed from the application site immediately after application. For the '10-s holding' group, the device was held in place after the application for 10 s to improve sample collection. The two groups of absorbent microbiopsy were set up to demonstrate how the application approach could affect the sample amount. The 10-s holding time was chosen as a clinically reasonable time to demonstrate that the application time affects the amount of recoverable sample.

The amount of RNA recovered from the two absorbent microbiopsy groups were 0.33 ± 0.39 ng for 'Immediate release' and 1.43 ± 0.88 ng for '10-s holding' (**Figure 3a**, $n = 20$), suggesting a 4-fold increase with the extra holding time. This indicates that applying the absorbent device with the 10-s holding time resulted in more RNA extracted. The difference may be due to the presence of increased blood sample in the absorbent layer (**Figure 3c**). Indeed, the 'Immediate release' group (**Figure 3b**) failed to collect a similar amount of blood with the absorbent layer as compared to the '10-s holding' group (**Figure 3c**). It should also be noted that most immediately released microbiopsies were close to the x-axis, suggesting they were negative events or displayed a very low amount of RNA. Therefore, the result validated the hypothesis that the holding time would have an impact on the performance of the device as it might take time for the blood to be

absorbed by the absorbent layer.

Since the device was designed for blood and skin sampling, qPCR was used to detect the expression of skin and blood biomarkers for both devices for comparison. We used tyrosinase, *TYR*, as a biomarker for melanocytes and *KRT14* as a biomarker for keratinocytes in the viable epidermis. Skin microbiopsy samples were included in the experiment for comparison. As shown in **Figure 4**, though skin and absorbent microbiopsies were applied differently due to the difference in design, the expression levels for both skin biomarkers *TYR* and *KRT14* were comparable for both devices as indicated by the data. White blood cell biomarkers (*CD3E*, T cells and *CD19*, B cells) were found to be more prevalent in absorbent microbiopsy samples than in skin microbiopsy samples. This result suggests that the absorbent microbiopsy performed better in blood collection but still maintained the capacity for capturing skin as compared to the skin microbiopsy (n = 5).

FIGURE AND TABLE LEGENDS:

Figure 1. The fabrication of absorbent microbiopsy. (a) The three-layer microneedle. (b) All parts of the device. (c) The assembled absorbent microbiopsy.

Figure 2. The absorbent microbiopsy was able to capture skin and blood samples simultaneously without leaving a scar on the left volar arm of male volunteer. (a) A comparison between the microneedles of absorbent and skin microbiopsies. (b) Application sites left by absorbent and skin microbiopsies 5 min after application. (c&d) Microneedles of absorbent and skin microbiopsies after application.

Figure 3. The absorbent microbiopsy captured more blood and RNA sample when applied for 10-s. (a) The 10-s post-application holding time resulted in a higher amount of RNA than releasing the device immediately (n = 20). Error bars represent S.D. from the mean (**** $p < 0.0001$). (b&c) Representative pictures of the absorbent microbiopsies after application with 'Immediate release' and '10-s holding' approaches.

Figure 4. The comparison of mRNA expression levels between skin and absorbent microbiopsies (n = 5). The gene expression had been normalized with reference gene *RPLP0*. Error bars represent S.D. from the mean (* $p < 0.05$).

DISCUSSION:

These results demonstrate that the absorbent microbiopsy can be used as a tool for simple and minimally invasive sampling of skin and blood mixture for molecular characterization. Device application in accordance with our protocol is essential for obtaining reliable results as shown by the difference in RNA amount recovered with different application protocols (**Figure 3**). Once the sample is extracted, the subsequent sample processing step for RNA extraction is highly similar to established protocols^{15,16}. Besides from the initial steps in RNA extraction that are modified for the absorbent microbiopsy, another key change is the use of RNase-free water to improve the results for downstream applications. Moreover, it is worth mentioning that the reference gene used in this study is *RPLP0*. *RPLP0*, whose function is well known for different cell and tissue

types¹⁷, has been reported as a suitable reference gene for use in non-melanoma skin cancers and precancerous lesions¹⁸.

One of the main limitations of the device is the removal of the microbiopsy from the device, which is time-consuming and potentially increases the chance of sample loss, especially for sensitive samples like RNA. Nevertheless, the issue can be overcome by pre-cooling all the sterile processing tools, such as the 2 mL microcentrifuge tubes, on dry ice.

The use of the absorbent microbiopsy is simple and does not require intensive training. Conventional biopsy is not necessary as microbiopsy permits molecular characterization with established molecular diagnosis techniques, such as RT-qPCR. To further quantify and demonstrate the sampling ability of absorbent microbiopsy, previous literature that involved RNA extraction from human skin tissue was investigated. From a typical 3.0 or 4.0 mm skin punch biopsy, three studies have reported the extracted RNA amounts ranged from 50 to 200 ng per mg of skin tissue^{19–21}. Comparing with the 1.43 ng of RNA that was recovered from the absorbent microbiopsy on average (**Figure 3**), the weight of sampled skin tissues is expected to range from 0.29-115 µg based on the same RNA-to-tissue ratio from skin punch biopsy studies.

This protocol is not without potential pitfalls, though some of the problems can be easily overcome. For example, the RNA extraction data suggested a huge variation even with the 10-s holding time (**Figure 3**). To address the problem, one potential solution involves optimizing the application protocol. Parameters such as force applied to the skin and holding time should be tested and optimized to reduce the variations in sample extraction. The other potential issue is the removal of microbiopsy from the device, which might impact the sample integrity and recovery. Although removing the microbiopsy for RNA extraction is an effective approach, the entire procedure is tedious, and the sample might be exposed to contamination in the process. Therefore, the modification of the sample processing protocol is highly desired in order to ensure sample integrity and prevent sample loss.

Once the above two issues are addressed, it is expected that the device will become a standard tool for clinical research. It is important to note that the device captures both skin and blood sample simultaneously and this should be taken into consideration when analyzing gene expression data. In conclusion, this protocol describes the details of performing absorbent microbiopsy as an easy and minimally invasive tool for combined skin and blood sampling and the subsequent sample processing for relative gene expression profiling.

ACKNOWLEDGMENTS:

We would like to acknowledge NHMRC Fellowships APP1109749 and APP1111216, University of Queensland Centennial Scholarship and International Postgraduate Research Scholarship.

DISCLOSURES:

No conflicts of interest declared.

REFERENCES:


1. Wang, C. Y. & Maibach, H. I. Why minimally invasive skin sampling techniques? A bright scientific future. *Cutaneous and Ocular Toxicology* **30**, 1–6 (2011).
2. Kirstein, O. D. *et al.* Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of *Leishmania donovani*. *International journal for parasitology* **47**, 609–616 (2017).
3. Lin, L. L. The skin microbiopsy. (The University of Queensland, 2015). doi:10.14264/uql.2015.848
4. Dhingra, N. *et al.* Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. *Journal of Allergy and Clinical Immunology* **134**, 362–372 (2014).
5. Chapman, P. B. *et al.* Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. *New England Journal of Medicine* **364**, 2507–2516 (2011).
6. Kirstein, O. D. *et al.* Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of *Leishmania donovani*. *International journal for parasitology* **47**, 609–616 (2017).
7. Lin, L. L. *et al.* Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling. *F1000Research* **2**, (2013).
8. Tom, L. N. *et al.* Skin microbiopsy for HPV DNA detection in cutaneous warts. *Journal of the European Academy of Dermatology and Venereology* **30**, e216–e217 (2016).
9. Sobarun, P. *et al.* Microbiopsy Biomarker Profiling in a Superficial Melanoma Resembling a Pigmented Basal Cell Carcinoma. *JAMA Dermatology* **153**, 334 (2017).
10. Banan, P., Lin, L. L., Lambie, D., Prow, T. & Soyer, H. P. Effects of Ex Vivo Skin Microbiopsy on Histopathologic Diagnosis in Melanocytic Skin Lesions. *JAMA Dermatology* **149**, 1107 (2013).
11. GraphPad - FAQ 1753 - Prism 3 -- Calculating “Unknown” Concentrations using a Standard Curve. Available at: <https://www.graphpad.com/support/faq/prism-3-calculating-unknown-concentrations-using-a-standard-curve/>. (Accessed: 10th August 2018)
12. Kubista, M. *et al.* The real-time polymerase chain reaction. *Molecular Aspects of Medicine* **27**, 95–125 (2006).
13. Goni, R., García, P. & Foissac, S. The qPCR data statistical analysis. 1–9 (2009).
14. *GraphPad Statistics Guide*. (1995).
15. Goldstein, N. B. *et al.* Isolating RNA from precursor and mature melanocytes from human vitiligo and normal skin using laser capture microdissection. *Experimental dermatology* **25**, 805–11 (2016).
16. Shearstone, J. R., Allaire, N. E., Campos-Rivera, J., Rao, S. & Perrin, S. Accurate and precise transcriptional profiles from 50 pg of total RNA or 100 flow-sorted primary lymphocytes. *Genomics* **88**, 111–121 (2006).
17. Bär, M., Bär, D. & Lehmann, B. Selection and Validation of Candidate Housekeeping Genes for Studies of Human Keratinocytes—Review and Recommendations. *Journal of Investigative Dermatology* **129**, 535–537 (2009).
18. Hoang, V. L. T. *et al.* RNA-seq reveals more consistent reference genes for gene expression studies in human non-melanoma skin cancers. *PeerJ* **5**, e3631 (2017).
19. Döbbeling, U. Simultaneous RNA and DNA Extraction from Biopsy Material, Culture Cells, Plants, and Bacteria. in *Nucleic Acid Protocols Handbook, The* 53–56 (Humana Press, 2000). doi:10.1385/1-59259-038-1:53

- 485 20. Bruning, O. *et al.* RNA isolation for transcriptomics of human and mouse small skin
486 biopsies. *BMC Research Notes* **4**, 438 (2011).
- 487 21. Berglund, S. R. *et al.* Optimized Methodology for Sequential Extraction of RNA and Protein
488 from Small Human Skin Biopsies. *Journal of Investigative Dermatology* **127**, 349–353 (2007).
489


Fig 1. The fabrication of absorbent microbiopsy

a) Microneedle layers

Whatman paper



b) Parts of absorbent microbiopsy





c) Assembled device





Lei et al Fig 1.


a) Absorbent vs. skin microbiopsies before application




Assembling



b) Application sites



c) Absorbent (10-s holding)



d) Skin (Immediate release)





Fig 4. The comparison of biomarker expression levels

[Click here to access/download;Figure;Fig 4. The comparison of biomarker expression levels.ai](#)



Lei et al Fig 4.

Name of Material/ Equipment	Company
Absorbent microbiopsy fabrication and sampling	
Absorbent Microbiopsy	Trajan Scientific and Medical
Whatman filter paper, Grade 1	Sigma Aldrich
RNA extraction	
PicoPure RNA Isolation Kit	ThermoFisher
UltraPure DNase/RNase-Free Distilled Water	ThermoFisher
2.0 mL Microcentrifuge Tube, Sterile	Thomas Scientific
Microcentrifuge 5415R	Eppendorf
cDNA synthesis	
SensiFAST cDNA Synthesis Kit	Bioline
CFX96 Touch Real-Time PCR Detection System	Bio-Rad
qPCR reaction and data analysis	
SensiFAST SYBR Lo-ROX Kit	Bioline
MicroAmp Optical Adhesive Film	ThermoFisher Scientific
MicroAmp Optical 384-Well Reaction Plate	ThermoFisher Scientific
QuantStudio 6 Flex Real-Time PCR System	ThermoFisher Scientific
GraphPad Prism (v6.04)	GraphPad
PCR primers	
<i>RPLP0</i> F	Sigma Aldrich
<i>RPLP0</i> R	Sigma Aldrich
<i>TYR</i> F	Sigma Aldrich
<i>TYR</i> R	Sigma Aldrich
<i>KRT14</i> F	Sigma Aldrich
<i>KRT14</i> R	Sigma Aldrich
<i>CD3E</i> F	Sigma Aldrich
<i>CD3E</i> R	Sigma Aldrich
<i>CD19</i> F	Sigma Aldrich
<i>CD19</i> R	Sigma Aldrich

Catalog Number	Comments/Description
N/A	https://www.trajanscimed.com/
WHA1001325	N/A
KIT0214	Including all buffer solutions described in protocol
10977015	Improving RNA quality in RNA elution step
1226S74	N/A
Z605212	N/A
BIO-65053	N/A
1855196	N/A
BIO-94005	Including reagents described in qPCR reaction steps
4311971	N/A
4343370	N/A
4485694	N/A
N/A; Windows version	Plotting and statistical analysis in qPCR data analysis steps
N/A	ATC AAC GGG TAC AAA CGA GTC
N/A	CAG ATG GAT CAG CCA AGA AGG
N/A	TCA GCA CCC CAC AAA TCC TAA
N/A	AAT CGG CTA CAG ACA ATC TGC
N/A	CCT CCT CCC AGT TCT CCT
N/A	ACA CCA CCT TGC CAT CG
N/A	CAA AGG GGA CAA AAC AAG GAG
N/A	GTT CTC CAG AGG GTC AGA TG
N/A	TTC TGC CTG TGT TCC CTT G
N/A	GCG TCA CTT TGA AGA ATC TCC T

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Absorbent microbiopsy sampling and RNA extraction for minimally invasive, simultaneous blood and skin analysis
Author(s):	Benson UW Lei, Miko Yamada, Van LT Hoang, Ross Flewell-Smith, Nhung Dang, Shoko Tomihara, Tarl W Prow

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐

Standard Access

☒

Open Access

Item 2: Please select one of the following items:

☒

The Author is **NOT** a United States government employee.

☐

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐

The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Tarl W Prow	
Department:	Future Industries Institute	
Institution:	University of South Australia, Australia	
Title:	Professor	
Signature:		Date: 04/06/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Editorial comments:

The manuscript has been modified and the updated manuscript, **58614_R1.docx**, is attached and located in your Editorial Manager account. **Please use the updated version to make your revisions.**

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

Author response: We have proofread the manuscript and fixed spelling and grammatical mistakes.

2. Please remove all headers from Representative Results.

Author response: The headers from Representative Results have been removed from the manuscript as suggested.

3. JoVE cannot publish manuscripts containing commercial language. This includes company names of an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. Examples of commercial language in your manuscript include SYBR Lo-ROX, Trajan Scientific and Medical, etc.

Author response: Generic terms have been adopted in the manuscript and all commercial language has been moved to the Table of Materials and Reagents.

4. Please provide the corresponding author and email of all authors in the manuscript.

Author response: Email addresses have been provided for each author and the corresponding author has been added at the end of the section.

5. Step 5.7: Calculation steps without graphical user interface cannot be filmed. For steps that are done using software with graphical user interface, a step-wise description of software usage must be included in the step. Please mention what button is clicked on in the software, or which menu items need to be selected to perform the step.

Author response: A step-wise description of software usage has been provided under step 5.7 in the Protocol section (see below)

'5.7. Calculate the RNA concentration of samples by interpolating from a standard curve prepared from templates with known concentrations.

5.7.1. Create a new experiment in the software.

5.7.2. Click 'Define and Set Up Standards' to set up serial dilution for plates.

5.7.3. *Select and arrange the wells for standards and samples. Click 'Apply'.*

5.7.4. *Click 'Analyze' in the Result tab to assess the standard curve. Confirm the slope, R2 value, amplification efficiency and error meet the experimental criteria.*

5.7.5. *Check the quantities of unknown samples visually on the standard curve based on their Ct values.*

Note: The construction of standard curve, including choice of dilution factor, is performed according to published protocols¹¹⁻¹³.

6. 5.8: Please add more details to your protocol steps. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.

Author response: A step-wise description has been provided to detail how step 5.8 is performed, and references to published materials about the approach have been added (see below).

‘5.8. Perform gene expression analysis of mRNA by using the Δ Ct method, Ct that is normalized to a reference gene.

5.8.1. *Subtract the Ct value of target gene from the Ct value of reference gene to obtain the Δ Ct value.*

5.8.2. *Average the Δ Ct values of technical replicates.*

5.8.3. *Plot and analyze gene expression with statistics software^{11,14} (see Table of Materials).*

Note: Alternatively, the gene expression analysis is performed according to published protocols¹³.

7. Please remove trademark (™) and registered (®) symbols from the Table of Equipment and Materials.

Author response: All trademark and registered symbols have been removed from the Table of Equipment and Materials.

8. Please revise the table of materials to include all essential supplies, reagents, and equipment. The table should include the name, company, and catalog number of all relevant materials in separate columns in an xls/xlsx file.

Author response: The Materials and Reagents table has been revised to contain the above information in an xls file (see attachment ‘Lei et al JoVE_Materials_09-08-2018.xls’).